Source comparison
How to Use CJC-1295 for Anti-Aging Protocol: Research Compound Comparison
| Peptide | Mechanism | Half-Life | Typical Dosing Frequency | IGF-1 Elevation vs Baseline | Receptor Selectivity | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog with extended half-life; amplifies endogenous GH pulses | 6–8 days | T
This comparison does not assign a generated winner or score.
- | Peptide | Mechanism | Half-Life | Typical Dosing Frequency | IGF-1 Elevation vs Baseline | Receptor Selectivity | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog with extended half-life; amplifies endogenous GH pulses | 6–8 days | Twice weekly | 1.5–2× at 12 weeks (when paired with secretagogue) | High selectivity for pituitary GHRH receptors; no cross-reactivity with ghrelin or cortisol pathways | Best choice for sustained anti-aging protocols due to infrequent dosing and stable IGF-1 elevation without receptor desensitization || Ipamorelin | Ghrelin mimetic; selectively stimulates GH release without affecting cortisol or prolactin | 2 hours | Daily or twice daily | 1.3–1.6× (monotherapy); 2.5–3× when paired with CJC-1295 | Highest selectivity among GHRPs; minimal off-target effects | Ideal pairing agent for CJC-1295 in protocols prioritizing hormonal balance and long-term use || GHRP-2 | Ghrelin mimetic; stimulates GH release with moderate cortisol and pro